ADC Therapeutics (ADCT) Enterprise Value (2019 - 2023)
Historic Enterprise Value for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$310.4 million.
- ADC Therapeutics' Enterprise Value rose 1849.84% to -$310.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$310.4 million, marking a year-over-year increase of 1849.84%. This contributed to the annual value of -$466544.0 for FY2022, which is 9989.84% up from last year.
- As of Q3 2023, ADC Therapeutics' Enterprise Value stood at -$310.4 million, which was up 1849.84% from -$347.5 million recorded in Q2 2023.
- ADC Therapeutics' Enterprise Value's 5-year high stood at -$115.55 during Q1 2020, with a 5-year trough of -$530.2 million in Q3 2021.
- In the last 5 years, ADC Therapeutics' Enterprise Value had a median value of -$466544.0 in 2022 and averaged -$145.5 million.
- As far as peak fluctuations go, ADC Therapeutics' Enterprise Value tumbled by 37998758.04% in 2021, and later skyrocketed by 3003.0% in 2023.
- Over the past 5 years, ADC Therapeutics' Enterprise Value (Quarter) stood at -$115.6 million in 2019, then soared by 99.57% to -$494416.0 in 2020, then plummeted by 92771.65% to -$459.2 million in 2021, then increased by 28.91% to -$326.4 million in 2022, then grew by 4.91% to -$310.4 million in 2023.
- Its Enterprise Value stands at -$310.4 million for Q3 2023, versus -$347.5 million for Q2 2023 and -$326441.0 for Q1 2023.